FDA OK's Novo Nordisk's Novoeight for hemophilia A
This article was originally published in Scrip
Executive Summary
The US FDA granted Novo Nordisk approval to market its new recombinant coagulation factor VIII product Novoeight (turoctocog alfa) for use in adults and children with hemophilia A to control and prevent bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.